Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

Urologic/Prostate

22nd Apr 2025

Plain language summary of the MAGNITUDE study on niraparib and abiraterone treatment for advanced prostate cancer

11th Feb 2025

Plain language summary of the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for advanced prostate cancer with specific DNA repair gene alterations

22nd Jan 2025

Plain language summary of the ENZAMET trial (ANZUP 1304): Enzalutamide combined with standard first-line therapy for metastatic hormone-sensitive prostate cancer

15th Nov 2024

The safety of relugolix combination therapy for advanced prostate cancer

18th Oct 2024

Enzalutamide in metastatic hormone-sensitive prostate cancer: A summary of the ARCHES and ENZAMET follow-up studies

30th Jul 2024

Plain language summary of TALAPRO-2 study: Talazoparib plus enzalutamide vs. placebo plus enzalutamide for advanced prostate cancer

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy